Takeda to cease distribution of Pfizer's Prevenar 13 and BeneFIX in Japan

8 August 2016

Japan’s largest drugmaker Takeda Pharma (TYO: 4502) has concluded an agreement to cease distribution of the pneumococcus conjugate vaccine Prevenar 13(pneumococcal 13-valent conjugate vaccine) and hemophilia B drug BeneFIX (nonacog alfa) that it currently distributes in Japan under an exclusive distribution agreement with US pharma giant Pfizer (NYSE: PFE), and that Pfizer, the manufacturer of the products, will begin selling them as of January 1, 2017.

Presently, due to changes in the business environment surrounding the two companies, the agreement was reached as a result of consultation between them in order to maximize the product value of the products.

Aside from this exclusive distribution agreement, the two companies have concluded a co-promotion agreement for the rheumatoid arthritis (RA) drugs Xeljanz (tofacitinib citrate) and Enbrel (etanercept), the co-promotion of which will be continued by both companies while the marketing will be continued by Takeda.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK